Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive top-line growth in 2025.Amgen also has some key pipeline assets in obesity ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

Repatha sales beat the Zacks Consensus Estimate of $555.0 million and our model estimate of $542.9 million. While 2024 sales were impacted by price erosion, in 2025, Amgen expects less price ...

Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and rare disease drugs, mostly products added from the Horizon acquisition, are driving sales.